T细胞表观遗传编程影响造血干细胞移植受者的免疫重建
本研究对造血干细胞移植(HSCT)受者的巨细胞病毒(CMV)特异性CD8+ T细胞进行转录组-染色质可及性分析,发现免疫重建稳定者干扰素/防御反应和细胞周期基因表达较高,染色质可及性增加;免疫重建不稳定者则表现出与慢性感染相似的转录和表观遗传特征。抑制HDAC6或JARID2可增强相关基因转录,提示表观遗传药物可能有助于促进HSCT受者的免疫重建。
要点
- 免疫重建稳定的HSCT受者CMV特异性T细胞高表达干扰素/防御反应和细胞周期基因,涉及PI3KCG、STAT5B、NFAT、RBPJ网络。
- 免疫重建不稳定者的CMV特异性T细胞高表达EGR和KLF因子、低表达JARID2,凋亡相关基因启动子和CpG富集区可及性增高。
- 抑制HDAC6或JARID2可增强差异反应相关基因的转录,提示表观遗传药物可能促进免疫重建。
核心结论
- HSCT受者T细胞中转录因子和染色质调节因子塑造不同的染色质可及性景观,既影响即时基因表达,也为后续信号反应做差异性准备。
- 表观遗传治疗可能是促进HSCT受者免疫重建的有前景策略。
研究设计与样本
- 研究对具有不同免疫重建效率的HSCT受者的CMV特异性CD8+ T细胞进行了转录组-染色质可及性景观分析。
主要发现
- 免疫重建稳定的HSCT受者CMV特异性T细胞在涉及PI3KCG、STAT5B、NFAT、RBPJ的互联网络中高表达干扰素/防御反应和细胞周期基因,HDAC6表达较低,免疫和T细胞受体信号通路基因增强子区域染色质可及性增加。
- 免疫重建不稳定的HSCT受者CMV特异性T细胞转录和表观基因组特征与其他未消退慢性感染中的T细胞反应有共性,包括EGR和KLF因子水平较高、JARID2表达较低,凋亡相关基因启动子和CpG富集区可及性较高。
- 通过抑制HDAC6或JARID2进行表观遗传靶向可增强与差异反应相关基因的转录。
临床怎么用
- 作者认为,靶向表观基因组修饰的药物可能具有增强HSCT受者免疫重建的治疗潜力。
- 作者提出,表观遗传治疗可能是促进HSCT受者免疫重建的有前景策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune reconstitution following hematopoietic stem cell transplantation (HSCT) is critical in preventing harmful sequelae in recipients with cytomegalovirus (CMV) infection. To understand the molecular mechanisms underlying immune reconstitution kinetics, we profiled the transcriptome-chromatin accessibility landscape of CMV-specific CD8+ T cells from HCST recipients with different immune reconstitution efficiencies. CMV-specific T cells from HSCT recipients with stable antiviral immunity expressed higher levels of interferon/defense response and cell cycle genes in an interconnected network involving PI3KCG, STAT5B, NFAT, RBPJ, and lower HDAC6, increasing chromatin accessibility at the enhancer regions of immune and T-cell receptor signaling pathway genes. By contrast, the transcriptional and epigenomic signatures of CMV-specific T cells from HSCT recipients with unstable immune reconstitution showed commonalities with T-cell responses in other nonresolving chronic infections. These signatures included higher levels of EGR and KLF factors that, along with lower JARID2 expression, maintained higher accessibility at promoter and CpG-rich regions of genes associated with apoptosis. Furthermore, epigenetic targeting via inhibition of HDAC6 or JARID2 enhanced the transcription of genes associated with differential responses, suggesting that drugs targeting epigenomic modifiers may have therapeutic potential for enhancing immune reconstitution in HSCT recipients. Taken together, these analyses demonstrate that transcription factors and chromatin modulators create different chromatin accessibility landscapes in T cells of HSCT recipients that not only affect immediate gene expression but also differentially prime cells for responses to additional signals. Epigenetic therapy may be a promising strategy to promote immune reconstitution in HSCT recipients.
引用
- Hardy K, Smith C, Tu WJ, et al. Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients. Blood Adv. 2018. PMID: 29563122. doi:10.1182/bloodadvances.2018015909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。